3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
69
Breast Neoplasms
51
Carcinoma, Non-Small-Cell Lung
28
Neoplasms
27
Myelodysplastic Syndromes
27
Advanced Solid Tumors
27
Advanced Solid Tumor
26
Prostatic Neoplasms
23
Stomach Neoplasms
19
Recurrence
18
Multiple Myeloma
18
Neoplasm Metastasis
17
Carcinoma, Hepatocellular
17
Ovarian Neoplasms
15
Lung Neoplasms
15
Pancreatic Neoplasms
14
Uterine Cervical Neoplasms
13
Solid Tumor
13
Sarcoma
13
Melanoma
13
Leukemia, Myelomonocytic, Chronic
13
Colorectal Neoplasms
11
Triple Negative Breast Neoplasms
10
Small Cell Lung Carcinoma
10
Lymphoma, Large B-Cell, Diffuse
10
Squamous Cell Carcinoma of Head and Neck
8
Myeloproliferative Disorders
8
Lymphoma, Non-Hodgkin
8
Esophageal Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Interventions
masitinib
4
Imatinib Mesylate
3
midostaurin
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Transplantation
1
Tacrolimus
1
Stem Cell Transplantation
1
Sodium Chloride
1
Single-Cell Gene Expression Analysis
1
Radiotherapy
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Injections
1
Hydroxychloroquine
1
Dasatinib
1
Cyclophosphamide
1
Cromolyn Sodium
1
Cladribine
1
Busulfan
1
BNT162 Vaccine
1
AK002
1
2019-nCoV Vaccine mRNA-1273
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mastocytosis
×
Injections
×
Clear all
NCT01333293
2016-01-18
XOLMA
University of Zurich
Phase 2/3
Completed
17 enrolled